DOCSLIB.ORG

Health in Pregnancy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Health in Pregnancy Health in Pregnancy Peter Ward Pathology North-Sydney Chemical Pathology, Royal North Shore Hospital Health in Pregnancy • Normal pregnancy is characterized by profound changes in almost every organ system in order to accommodate the demands of the fetoplacental unit. • Large amounts of oestrogens, progesterone and corticosteroids produced affect various metabolic, physiological and endocrine systems. • Many normal Reference Intervals are not appropriate for pregnancy. Health in Pregnancy • Normal pregnancy lasts ~ 40 weeks • Divided into three trimesters each of ~ 13 weeks • By 10 weeks embryo has developed most major structures – now referred to as a fetus • At end of first trimester fetus weight 13g • Rapid foetal growth in T2 (13-26w) – 700g by end of T2 • T3 (26-40w). Organ maturation; growth rate decelerates. Weight ~ 3200g at term Health in Pregnancy • Placenta is the primary link between the mother and fetus. • Placenta keeps the maternal and fetal circulation separate, nourishes the fetus, eliminates fetal waste and produces hormones vital to the pregnancy • Placental hormone production generally increases in proportion to the increase in placental mass. • Exception is hCG (human chorionic gonadotropin) hCG • hCG is produced by the trophoblast which later develops into the placenta • hCG maintains the corpus luteum, enabling it to produce progesterone until placental progesterone production becomes established (six weeks of gestation). Actions of progesterone prevents menses thus allowing pregnancy to continue. • Serum or urine hCG often used in the diagnosis of pregnancy hCG • Glycoprotein; dimer • α subunit – common to hCG, LH, FSH & TSH • β subunit –specific, receptor binding • Detectable 6 - 8 days after conception • Concentration doubles every two days • Concentration peaks at 10 weeks and then declines • Levels are very highly variable, and not useful for estimating gestational age Maternal adaption in pregnancy • Numerous physiological changes occur during pregnancy to accommodate the maternal and foetal needs • Most begin soon after conception and continue until late gestation • These physiologic adaptations result in many significant changes in laboratory test values. Pregnancy related Ref Int !!! • Most pregnancies proceed normally so little need for laboratory testing Respiratory changes • Increased ventilation allows maintenance of high-normal pO2 – O2 consumption increases by 20% due to metabolic demands of the placenta, foetus, and maternal organs. • Mild respiratory alkalosis; fall in pCO2 from 40 mmHg to 27–32 mmHg – Thought to assist the foetus to eliminate CO2 across the placenta • Altered set point of central respiratory centres – progesterone effect- increasing the sensitivity of the medulla to CO2 • Arterial pH normal to slightly alkalotic (7.40 – 7.45) after renal compensation Haemodynamic changes • Increased cardiac output • Decreased systemic vascular resistance and blood pressure • Expansion of plasma volume ( 30-50% ↑ over non - pregnant) • ↑ red blood cell mass (< than plasma volume expansion so mild ↓ in Haematocrit). • P.R.A. ↑, Atrial Natriuretic peptide ↓ - suggests plasma volume underfilling as true volume expansion would result in the opposite (ie ↓ P.R.A. and ↑ANP) Effects of Haemodilution and Changes in Renal function • Many of the biochemical changes in pregnancy are due either to ↑ in blood volume or ↑ Renal Function due to ↑ renal perfusion →↑GFR . – ↑ in volume → dilution of some analytes ie Albumin (34g/L in late pregnancy), Ferritin – ↑Renal Clearance → ↓ serum [Creatinine, Urea] over much of the pregnancy & ↓ [Uric Acid] (Trimester 1,2) – Creatinine decreases by 35 umol/L to 35 – 70 umol/L – eGFR equations are inaccurate during pregnancy; • MDRD underestimates GFR during pregnancy – Urinary protein excretion increases from 100 mg/day to 180–200 mg/day in the third trimester Sodium and Water • Water retention: average increase at term of 3 L total • Plasma osmolality falls to a new set point of ~270 mOsm/kg with a proportional decrease in Sodium by 4 – 5 mmol/L – Hyponatremia of pregnancy mediated by hormonal factors and correlates closely with increased hCG production – Physiological responses to changes in osmolality above or below the new set point (ie, thirst and ADH release) are intact. – Correction of the hyponatremia is both unnecessary and ineffective Liver Function Tests • Albumin decreases during the first trimester, due to haemodilution • ALP 2 – 4× normal in third trimester, primarily due to placental synthesis • GGT reduced two fold • ALT and AST minor decreases • Bilirubin is slightly decreased • Total bile acids are increased in second and third trimesters • PT unchanged; fibrinogen increases in late pregnancy. Other changes • Lipase and LD double • Some transport proteins (TBG, CBG and SHBG) increase markedly Iron, B12 and folate • Foetal haematopoiesis requires supply of iron, vitamin B12 and folate • Average total maternal iron requirements are ~ 1000 mg – 300 mg for the foetus and placenta, 500 mg for maternal haemoglobin. – 200 mg is shed through the gut, urine, and skin. – Women taking iron supplements have 10 g/L higher Hb Hypothalamic hormones Hypothalamic hormones may be produced by the placenta • GnRH increases, with unknown physiological significance – Mainly from placenta, possible role in placental growth and function • CRH increases exponentially throughout pregnancy – Produced by placenta – In Placental HPA axis, CRH is stimulated by cortisol, ie, positive feedback loop – Rise in CRH may have possible role in initiation of labour • GHRH unchanged, but GH is higher due to placental secretion • Somatostatin decreases with advancing gestation – Inhibits human placental lactogen (hPL), a hormone that causes insulin resistance. – Structure of hPL is 96% homologous with GH and 67% with prolactin – Potent growth and lactogenic properties • TRH unchanged Anterior Pituitary hormones • The anterior lobe enlarges up to 3× due to hyperplasia and hypertrophy of lactotrophs • Prolactin increases, peaking at delivery – Probably due to increasing estradiol during pregnancy – Preparation for lactation – Variable magnitude of increase • At term: 4,000 IU/L (700 – 12,000) Anterior Pituitary hormones • LH and FSH suppression with decreased response to GnRH – Due to the high estradiol and progesterone – Also due to inhibin A and inhibin B produced by placenta • GH increased – Pituitary GH production is replaced by placental-GH, which peaks at 35 weeks. • ACTH increased – Probably due to placental CRH, stimulated by cortisol – Pregnancy is a state of relative hypercortisolism – Increases in serum, salivary, and urinary free cortisol • TSH is reduced in the first trimester – Due to the thyrotropic effects of hCG – TSH retains its normal circadian rhythm (nocturnal surge), indicating an intact axis – May be elevated at term due to increased iodine clearance and placental degradation of thyroid hormone Calcium metabolism • Elevated 1,25-(OH)2Vit D • VitD metabolism is uncoupled from calcium – By second trimester 1,25-di(OH)2Vit D levels increase >2x without change in calcium – May be due to placental 1α-hydroxylase, since increases in 1,25-(OH)2Vit D in pregnancy do not follow PTH • PTH declines in the early half of pregnancy reaches a nadir and then rises – May be due to inhibition from 1,25- di(OH)2Vit D or increased intestinal calcium absorption Thyroid function • Normal pregnancy is a euthyroid state • Thyroxine binding globulin (TBG) increases 2× due to oestrogen – Total T4 and T3 concentrations rise during the first half of pregnancy, plateauing at approximately 20/40 • hCG has weak thyroid-stimulating activity – high levels of hCG in first trimester lead to suppression of TSH resulting in a corresponding slight increase in free T4 and Free T3. • As hCG declines, TSH rises slightly and free T4 and T3 decline • Need to have method specific Free Thyroid Hormone Ref Int Adrenal • Stimulation of the renin-angiotensin-aldosterone system – Due to reductions in vascular resistance and blood pressure • Aldosterone increases markedly during first trimester and continues to increase to 4 – 6× URL – Progesterone competes with aldosterone for binding to the mineralocorticoid receptor – Subsequent natriuretic effect • Atrial natriuretic peptide decreases as renin and aldosterone increase – Consistent with a state of effective hypovolemia • Cortisol increases due to placental CRH – CBG also increases 2–3×, so that total cortisol is increased to a greater degree than free cortisol • SHBG increases 6× – Total testosterone increases – Free testosterone is unchanged, but increases in third trimester – Androstenedione also increases in the third trimester – DHEAS decreases due to increased metabolic clearance aldosterone progesterone Metabolic Adaption • Late in gestation, maternal physiology is primarily influenced by placental hormones • Effect on both glucose and lipid metabolism to ensure that the fetus has an adequate supply of fuel and nutrients at all times. • Late pregnancy →↑fetal growth and demand for nutrients. • Maternal response is to switch from CHO to fat utilization – Facilitated by both insulin resistance and ↑ lipolytic hormones – Glucose is reserved for the fetus – Alternative fuels made available for the mother Glucose metabolism • Changes in maternal carbohydrate and fat metabolism ensure a supply of fuel for the fetus • Hyperplasia of pancreatic β cells with increased insulin secretion – Due to human placental lactogen – Insulin levels are higher both in
Load more

Recommended publications
  • Strategies to Increase ß-Cell Mass Expansion
    This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ Strategies to increase -cell mass expansion Drynda, Robert Lech Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 Strategies to increase β-cell mass expansion A thesis submitted by Robert Drynda For the degree of Doctor of Philosophy from King’s College London Diabetes Research Group Division of Diabetes & Nutritional Sciences Faculty of Life Sciences & Medicine King’s College London 2017 Table of contents Table of contents .................................................................................................
    [Show full text]
  • LANTUS® (Insulin Glargine [Rdna Origin] Injection)
    Rev. March 2007 Rx Only LANTUS® (insulin glargine [rDNA origin] injection) LANTUS® must NOT be diluted or mixed with any other insulin or solution. DESCRIPTION LANTUS® (insulin glargine [rDNA origin] injection) is a sterile solution of insulin glargine for use as an injection. Insulin glargine is a recombinant human insulin analog that is a long-acting (up to 24-hour duration of action), parenteral blood-glucose-lowering agent. (See CLINICAL PHARMACOLOGY). LANTUS is produced by recombinant DNA technology utilizing a non- pathogenic laboratory strain of Escherichia coli (K12) as the production organism. Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain. Chemically, it is 21A- B B Gly-30 a-L-Arg-30 b-L-Arg-human insulin and has the empirical formula C267H404N72O78S6 and a molecular weight of 6063. It has the following structural formula: LANTUS consists of insulin glargine dissolved in a clear aqueous fluid. Each milliliter of LANTUS (insulin glargine injection) contains 100 IU (3.6378 mg) insulin glargine. Inactive ingredients for the 10 mL vial are 30 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, 20 mcg polysorbate 20, and water for injection. Inactive ingredients for the 3 mL cartridge are 30 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, and water for injection. The pH is adjusted by addition of aqueous solutions of hydrochloric acid and sodium hydroxide. LANTUS has a pH of approximately 4. CLINICAL PHARMACOLOGY Mechanism of Action: The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism.
    [Show full text]
  • Insulin Aspart Sanofi, If It Is Coloured Or It Has Solid Pieces in It
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Insulin aspart Sanofi 100 units/ml solution for injection in vial Insulin aspart Sanofi 100 units/ml solution for injection in cartridge Insulin aspart Sanofi 100 units/ml solution for injection in pre-filled pen 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml solution contains 100 units insulin aspart* (equivalent to 3.5 mg). Insulin aspart Sanofi 100 units/ml solution for injection in vial Each vial contains 10 ml equivalent to 1,000 units insulin aspart. Insulin aspart Sanofi 100 units/ml solution for injection in cartridge Each cartridge contains 3 ml equivalent to 300 units insulin aspart. Insulin aspart Sanofi 100 units/ml solution for injection in pre-filled pen Each pre-filled pen contains 3 ml equivalent to 300 units insulin aspart. Each pre-filled pen delivers 1-80 units in steps of 1 unit. *produced in Escherichia coli by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection). Clear, colourless, aqueous solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Insulin aspart Sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. 4.2 Posology and method of administration Posology The potency of insulin analogues, including insulin aspart, is expressed in units, whereas the potency of human insulin is expressed in international units.
    [Show full text]
  • Placental Growth Hormone-Related Proteins and Prolactin-Related Proteins
    Placental Growth Hormone-Related Proteins and Prolactin-Related Proteins The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Haig, D. 2008. Placental growth hormone-related proteins and prolactin-related proteins. Placenta 29: 36-41. Published Version doi:10.1016/j.placenta.2007.09.010 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11148777 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Placental growth hormone-related proteins and prolactin-related proteins. David Haig Department of Organismic and Evolutionary Biology, Harvard University, 26 Oxford Street, Cambridge MA 02138. e-mail: [email protected] phone: 617-496-5125 fax: 617-495-5667 Keywords: GH, PRL, placenta, endometrial glands, placental lactogen The placentas of ruminants and muroid rodents express prolactin (PRL)-related genes whereas the placentas of anthropoid primates express growth hormone (GH)-related genes. The evolution of placental expression is associated with acclerated evolution of the corresponding pituitary hormone and destabilization of conserved endocrine systems. In particular, placental hormones often evolve novel interactions with new receptors. The adaptive functions of some placental hormones may be revealed only under conditions of physiological stress. Introduction Placental hormones are produced by offspring, but act on receptors of mothers. As such, placental hormones and maternal receptors are prime candidates for the expression of parent-offspring conflict [1,2].
    [Show full text]
  • OZEMPIC (Semaglutide) Injection, for Subcutaneous Use Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙CONTRAINDICATIONS∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ These highlights do not include all the information needed to use Personal or family history of medullary thyroid carcinoma or in patients OZEMPIC® safely and effectively. See full prescribing information with Multiple Endocrine Neoplasia syndrome type 2 (4). for OZEMPIC. Known hypersensitivity to OZEMPIC or any of the product components (4). OZEMPIC (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017 ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙WARNINGS AND PRECAUTIONS∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Pancreatitis: Has been reported in clinical trials. Discontinue promptly if WARNING: RISK OF THYROID C-CELL TUMORS pancreatitis is suspected. Do not restart if pancreatitis is confirmed (5.2). See full prescribing information for complete boxed warning. Diabetic Retinopathy Complications: Has been reported in a clinical trial. Patients with a history of diabetic retinopathy should be monitored (5.3). In rodents, semaglutide causes thyroid C-cell tumors. It is Never share an OZEMPIC pen between patients, even if the needle is unknown whether OZEMPIC causes thyroid C-cell tumors, changed (5.4). including medullary thyroid carcinoma (MTC), in humans as Hypoglycemia: When OZEMPIC is used with an insulin secretagogue or the human relevance of semaglutide-induced rodent thyroid C- insulin, consider lowering the dose of the secretagogue or insulin to reduce cell tumors has not been determined (5.1, 13.1). the risk of hypoglycemia (5.5). OZEMPIC is contraindicated in patients with a personal or Acute Kidney Injury: Monitor renal function in patients with renal family history of MTC or in patients with Multiple Endocrine impairment reporting severe adverse gastrointestinal reactions (5.6). Neoplasia syndrome type 2 (MEN 2).
    [Show full text]
  • Pathophysiology of Gestational Diabetes Mellitus: the Past, the Present and the Future
    6 Pathophysiology of Gestational Diabetes Mellitus: The Past, the Present and the Future Mohammed Chyad Al-Noaemi1 and Mohammed Helmy Faris Shalayel2 1Al-Yarmouk College, Khartoum, 2National College for Medical and Technical Studies, Khartoum, Sudan 1. Introduction It is just to remember that “Pathophysiology” refers to the study of alterations in normal body function (physiology and biochemistry) which result in disease. E.g. changes in the normal thyroid hormone level causes either hyper or hypothyroidism. Changes in insulin level as a decrease in its blood level or a decrease in its action will cause hyperglycemia and finally diabetes mellitus. Scientists agreed that gestational diabetes mellitus (GDM) is a condition in which women without previously diagnosed diabetes exhibit high blood glucose levels during pregnancy. From our experience most women with GDM in the developing countries are not aware of the symptoms (i.e., the disease will be symptomless). While some of the women will have few symptoms and their GDM is most commonly diagnosed by routine blood examinations during pregnancy which detect inappropriate high level of glucose in their blood samples. GDM should be confirmed by doing fasting blood glucose and oral glucose tolerance test (OGTT), according to the WHO diagnostic criteria for diabetes. A decrease in insulin sensitivity (i.e. an increase in insulin resistance) is normally seen during pregnancy to spare the glucose for the fetus. This is attributed to the effects of placental hormones. In a few women the physiological changes during pregnancy result in impaired glucose tolerance which might develop diabetes mellitus (GDM). The prevalence of GDM ranges from 1% to 14% of all pregnancies depending on the population studied and the diagnostic tests used.
    [Show full text]
  • Type 2 Diabetes Adult Outpatient Insulin Guidelines
    Diabetes Coalition of California TYPE 2 DIABETES ADULT OUTPATIENT INSULIN GUIDELINES GENERAL RECOMMENDATIONS Start insulin if A1C and glucose levels are above goal despite optimal use of other diabetes 6,7,8 medications. (Consider insulin as initial therapy if A1C very high, such as > 10.0%) 6,7,8 Start with BASAL INSULIN for most patients 1,6 Consider the following goals ADA A1C Goals: A1C < 7.0 for most patients A1C > 7.0 (consider 7.0-7.9) for higher risk patients 1. History of severe hypoglycemia 2. Multiple co-morbid conditions 3. Long standing diabetes 4. Limited life expectancy 5. Advanced complications or 6. Difficult to control despite use of insulin ADA Glucose Goals*: Fasting and premeal glucose < 130 Peak post-meal glucose (1-2 hours after meal) < 180 Difference between premeal and post-meal glucose < 50 *for higher risk patients individualize glucose goals in order to avoid hypoglycemia BASAL INSULIN Intermediate-acting: NPH Note: NPH insulin has elevated risk of hypoglycemia so use with extra caution6,8,15,17,25,32 Long-acting: Glargine (Lantus®) Detemir (Levemir®) 6,7,8 Basal insulin is best starting insulin choice for most patients (if fasting glucose above goal). 6,7 8 Start one of the intermediate-acting or long-acting insulins listed above. Start insulin at night. When starting basal insulin: Continue secretagogues. Continue metformin. 7,8,20,29 Note: if NPH causes nocturnal hypoglycemia, consider switching NPH to long-acting insulin. 17,25,32 STARTING DOSE: Start dose: 10 units6,7,8,11,12,13,14,16,19,20,21,22,25 Consider using a lower starting dose (such as 0.1 units/kg/day32) especially if 17,19 patient is thin or has a fasting glucose only minimally above goal.
    [Show full text]
  • Insulin Aspart (Nvolog): Important Patient Information
    What is most important to remember? If you have questions: Strong Internal Medicine • Insulin aspart (Novolog®) is used to lower blood sugar. It is Ask your doctor, nurse or pharmacist for important to use this medicine as more information about insulin aspart directed by your doctor (Novolog®) • Do not start any new medicines, over-the-counter drugs or herbal remedies without talking to your doctor • Tell all doctors, dentists and pharmacists that you are using insulin aspart (Novolog®) • insulin aspart (Novolog®) can cause low blood sugar. Always Strong Internal Medicine keep a source of sugar handy for 601 Elmwood Avenue times when your blood sugar gets Ambulatory Care Facility, 5th Floor too low Rochester, NY 14642 Phone: (585) 275 -7424 Insulin Aspart • Do not use your insulin if it (Novolog®): Visit our website at: becomes cloudy or has particles www.urmc.rochester.edu/medicine/ - Important Patient Information in it general-medicine/patientcare/ • Throw away all opened insulin after 28 days, even if it is not used up What does insulin aspart (Novolog®) do? Are there any interactions with other drugs that I need What are some things that I need to be aware of when to worry about? taking insulin aspart (Novolog®)? • It is used to lower blood sugar in patient with high blood sugar (diabetes) • There are many drug interactions that may increase • Tell your doctor or pharmacist if you have an allergy to How should insulin aspart (Novolog®) be used? your risk of side effects insulin, or any other drugs, foods, or substances • Use this
    [Show full text]
  • Safety of Insulin Lispro and a Biosimilar Insulin Lispro When
    DSTXXX10.1177/1932296817753644Journal of Diabetes Science and TechnologyThrasher et al 753644research-article2018 Original Article Journal of Diabetes Science and Technology 2018, Vol. 12(3) 680 –686 Safety of Insulin Lispro and a Biosimilar © 2018 Diabetes Technology Society Insulin Lispro When Administered Reprints and permissions: sagepub.com/journalsPermissions.nav Through an Insulin Pump DOI:https://doi.org/10.1177/1932296817753644 10.1177/1932296817753644 journals.sagepub.com/home/dst James Thrasher, MD1, Howard Surks, MD2, Irene Nowotny, PhD3, Suzanne Pierre, MSc4, Baerbel Rotthaeuser, PhD3, Karin Wernicke-Panten, MD3, and Satish Garg, MD5 Abstract Background: SAR342434 (U100; SAR-Lis; insulin lispro) is a biosimilar/follow-on to insulin lispro (U100; Ly-Lis). Similar pharmacokinetics/pharmacodynamics between the two products has been demonstrated in a hyperinsulinemic euglycemic clamp study. The current study evaluated the safety of SAR-Lis and Ly-Lis when administered by continuous subcutaneous insulin infusion (CSII; insulin pumps). Methods: This was a randomized, open-label, 2 × 4-week, two-arm crossover study in 27 patients with type 1 diabetes mellitus (NCT02603510). The main outcome was the incidence of infusion set occlusions (ISOs), defined as failure to correct hyperglycemia (plasma glucose ≥≥ 300 mg/dl) by 50 mg/dl within 60 minutes by insulin bolus via the pump. Secondary outcomes included intervals between infusion set changes, treatment-emergent adverse events (TEAEs) including infusion site, hypersensitivity reactions and hypoglycemic events, and safety. Results: The number of patients reporting at least one ISO was small: 6/25 patients on SAR-Lis reported 14 ISOs and 4/27 on Ly-Lis reported nine ISOs. The estimated difference in ISO risk for SAR-Lis versus Ly-Lis was 7.9% (95% CI, –1.90 to 17.73).
    [Show full text]
  • Insulin Products and the Cost of Diabetes Treatment
    November 19, 2018 Insulin Products and the Cost of Diabetes Treatment Insulin is a hormone that regulates the storage and use of would involve a consistent insulin level between meals sugar (glucose) by cells in the body. When the pancreas combined with a mealtime level of insulin that has a rapid does not make enough insulin (type 1 diabetes) or it cannot onset and duration of action to match the glucose peak that be used effectively (type 2 diabetes), sugar builds up in the occurs after a meal. The original insulin, also called regular blood. This may lead to serious complications, such as heart insulin, is a short-acting type of product with a duration of disease, stroke, blindness, kidney failure, amputation of action of about 8 hours, making it less suitable for toes, feet, or limbs. Prior to the discovery of insulin providing 24-hour coverage. treatment, type 1 diabetics usually died from this disease. In the late 1930s through the 1950s, regular insulin was There were 23.1 million diagnosed cases of diabetes in the altered by adding substances (protamine and zinc) to gain United States in 2015 according to the Centers for Disease longer action; these are called intermediate-acting insulins. Control and Prevention (CDC). Adding an estimated 7.2 One such advance (neutral protamine Hagedorn, or NPH) million undiagnosed cases brings the total to 30.3 million was patented in 1946 and is still in use today. It allowed for (9.4% of U.S. population). People with type 1 diabetes, the combination of two types of insulin in premixed vials about 5% of U.S.
    [Show full text]
  • Insulin Glargine (HOE901) First Responsibilities: Understanding the Data and Ensuring Safety
    EDITORIAL Insulin Glargine (HOE901) First responsibilities: understanding the data and ensuring safety n this issue, Heinemann et al. (1) and Rat- decline in activity through the duration of other journals. They leave the reader with ner et al. (2) provide the results of stud- the 30-h study. The authors conclude that a sense of promise, but without the firm Iies of insulin glargine (formerly known as insulin glargine provides a flatter metabolic conviction that insulin glargine is clearly HOE901), the most recent addition to the profile than NPH insulin. Theoretically, this superior to other long-acting forms of growing family of insulin analogs and for- could prove to be advantageous in accom- insulin. The pharmacodynamic study sug- mulations. The authors report insulin modating the basal insulin requirements of gests that the peakless profile of action glargine’s pharmacodynamic characteristics patients with diabetes. should provide an advantage that can be (1) and data concerning its safety and effi- Ratner et al. (2) report initial results for used to produce clinically meaningful cacy when administered to subjects with the U.S. Study Group of Insulin Glargine in improvements in glycemic control. The type 1 diabetes who were treated with reg- Type 1 Diabetes. In their article, they clinical trial’s demonstration of a reduction ular insulin (2). Insulin glargine is produced describe the results of a large randomized in hypoglycemia and in fasting plasma glu- by recombinant DNA technology with 2 prospective 28-week trial of insulin cose levels appears to provide an opportu- modifications of the native human insulin glargine versus NPH insulin.
    [Show full text]
  • Fetal Growth Signals
    Arch Dis Child: first published as 10.1136/adc.64.1_Spec_No.53 on 1 January 1989. Downloaded from Archives of Disease in Childhood, 1989, 64, 53-57 Current topic Fetal growth signals R D G MILNER AND D J HILL Department of Paediatrics, Children's Hospital, Sheffield Human fetal growth is not uniform. Tissue patterns growth factor fi like peptide is found in the vegetal and organ primordia are established during embryo- pole ectoderm of the early Xenopus embryo and is genesis, then from the end of the first trimester and transcribed by a maternally derived gene designated throughout the second the fetus undergoes massive Vgl. An ectodermal cell line, XTC, from the meta- hyperplasia. In the third trimester further organ morphosing tadpole releases a transforming growth modelling and functional maturation occur in pre- factor I8 like peptide in vitro.5 In the 11-18 day fetal paration for extrauterine life. Each aspect ofdevelop- mouse transforming growth factor 3 can be detected ment requires orchestrated intercellular signalling at in bone and connective tissue, particularly that two levels. The release of peptide growth factors derived from neural crest such as palate, larynx, and the modulation of an extracellular matrix are facial mesenchyme, and teeth.6 Staining was most paracrine actions that occur within cell populations intense at sites of tissue morphogenesis affecting and between adjacent germ layers. In contrast, mesodermal and epithelial interaction such as hair endocrine hormones may stimulate growth non- follicles, teeth, and secondary palate. copyright. specifically or promote specific maturational events. Recently both fibroblast growth factor and trans- The interactions between paracrinology, endocrino- forming growth factor i have been shown to exert logy, and environmental constraints to growth remarkable effects on embryonal morphology.
    [Show full text]